Egypt pharmaceutical market: size, growth and outlook 2026–2032

One of the largest manufacturing bases in MENA and a low-cost source for GCC tenders. Published estimates normalised to 2025 range from USD 1.2 bn to USD 8.5 bn; the Consulting Wallah central estimate is USD 8.5 bn, growing at about 12% a year to USD 18.8 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by large growing population (~118.4 mn in 2025) and rising chronic disease burden; eDA-approved price increases post EGP float (2.2k products / 38% of registered products by end-2024) lifting market value; government localisation drive: 91.3% self-sufficiency, 31 new factories licensed, 180 antibiotics and 129 APIs localised.

Context that matters for buyers and suppliers: Egypt has >170 manufacturing facilities (179 factories), 11 internationally certified (WHO/EMA), 2.3k production lines of which 986 pharmaceutical. Egypt is MENA's largest drug manufacturing base, ~30% of regional market; 170-200 pharma companies. EIPICO accounts for ~25% of Egypt's pharma exports; 330 mn packs across 51 lines. Gypto Pharma (launched 2021): 100 mn packs/yr, targeting 150-200 mn by 2025; exports USD 2.5-3 mn.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 1.2 bn–USD 8.5 bn; differences are mostly scope.

Included: prescription and OTC pharmaceuticals, biologics and vaccines across hospital, retail and government channels. Excluded: medical devices, nutrition. Figures at ex-manufacturer vs retail prices differ by 20–40%, which explains part of the published range.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Egypt has >170 manufacturing facilities (179 factories), 11 internationally certified (WHO/EMA), 2.3k production lines of which 986 pharmaceutical (EDA via Enterprise / Cabinet via Amwal Al Ghad)
• Egypt is MENA's largest drug manufacturing base, ~30% of regional market; 170-200 pharma companies (Business Monthly)
• EIPICO accounts for ~25% of Egypt's pharma exports; 330 mn packs across 51 lines (Amwal Al Ghad)
• Gypto Pharma (launched 2021): 100 mn packs/yr, targeting 150-200 mn by 2025; exports USD 2.5-3 mn (Amwal Al Ghad)
• Top 50 imported APIs make up 78% of human pharma raw-material imports (Arab Finance)
• Egyptian Pharmacopeia covers 2,500 of a targeted 3,400 drugs; WHO ML3 achieved Dec 2024 with ML4 planned (Business Monthly)
• Ibn Sina Pharma holds 30.8% distribution market share (2024 revenue +64%) (EFG Hermes via Enterprise)
• VACSERA complex capable of 700 mn vaccine doses/yr; AstraZeneca Egypt invested USD 50 mn to reach 900 mn tablets/yr (Amwal Al Ghad)
• 50 local alternatives to imported drugs save USD 182 mn/yr; localised antibiotics/APIs previously cost USD 633.7 mn/yr to import (Cabinet via Amwal Al Ghad)

Where the GCC and India sit

• Egypt market value: EGP 422 bn (~USD 8.5 bn) (2025) — EDA via Arab Finance
• Egypt market value: EGP 307 bn (2024) — EDA Chairman via Enterprise
• Egypt pharma exports: ~USD 1.3 bn (target USD 3 bn by 2030) (2025) — EDA via Arab Finance
• Egypt pharma exports: USD 447.1 mn (vs USD 270 mn in 2019) (2024) — Cabinet via Amwal Al Ghad
• Egypt pharma exports forecast: USD 466.5 mn (2029) — Fitch Solutions via Amwal Al Ghad
• Egypt annual pharma import bill: ~USD 3 bn (≈75% is APIs) (2025) — Business Monthly

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: biosimilars manufacturing (EIPICO 3 plant 95% complete, >USD 100 mn); aPI and excipient localisation (30 of 280 inactive ingredients targeted; EGP 80 mn raw-material hub); export to 147+ markets incl. Saudi Arabia; Gulf and Africa expansion.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers: registration and a strong local agent decide access; serialisation and GMP inspection readiness shorten the path; localisation stories win public tenders.
• Hospital leaders: class-level lots, biosimilars and IV→oral switch programmes are the three savings levers; the drug repository lists the class members.
• Distributors: buyers increasingly want data (catalogue, serialisation events, fill rates) as much as product.

1. Arab Finance, Egypt pharma market hits EGP 422 billion in 2025 — arabfinance.com
2. Zawya, Egypt's pharma market hits $8.4bln in 2025, ranks 26th globally — zawya.com
3. Enterprise, Egypt's pharma sector expands amid price hikes and regulatory shifts — enterpriseam.com
4. Business Monthly (AmCham Egypt), Egypt Powers Up Pharma Industry With Localization, Ambitious Export Goals — businessmonthlyeg.com
5. Amwal Al Ghad, Egypt scales up drug output, sees $466m in pharma exports by 2029 — en.amwalalghad.com
6. TechSci Research, Egypt Pharmaceutical Market Size, Share, Forecast 2031 — techsciresearch.com
7. Egyptian Drug Authority (EDA) via Arab Finance / Zawya (2026-06) — EGP 422 bn (~USD 8.5 bn); 4 bn units (2025) to — (), CAGR ~15% CAGR; +37% y-o-y in value (2025); scope: Country: Egypt total pharma market at ex-market value; ranked 26th globally in 2025 (30th in 2024) — source
8. TechSci Research (2026-09) — USD 1,245.10 mn (2025) to USD 1,823.95 mn (2031), CAGR 6.57% (2026-2031); scope: Country: Egypt; figure appears to be a narrower scope/ex-factory basis than EDA's USD 8.5 bn; generics 62%, Rx 83%, retail pharmacies 68%, Cairo 35% — source
9. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
10. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.